Here are the 10-K annual reports from Myriad Genetics Inc (MYGN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MYGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYGN filings page.
Myriad Genetics outlines its 2025 business strategy and operations in oncology, women’s health, and mental health, centered on molecular diagnostics and precision medicine. The company emphasizes hereditary cancer testing, prenatal screening, and the GeneSight pharmacogenomic test for psychiatric medications.
Growth priorities include building a comprehensive Cancer Care Continuum portfolio, expanding Precise MRD for molecular residual disease, and launching the FirstGene 4‑in‑1 prenatal screen in 2026. Myriad highlights collaborations with PATHOMIQ and SOPHiA GENETICS, strong customer satisfaction (Net Promoter Score above 70), and significant R&D investment of $106.8 million in 2025.
The report notes competition from major diagnostic players, dependence on payer reimbursement, evolving FDA, CLIA, EU and UK regulation, and extensive IP and licensing arrangements. As of June 30, 2025, non‑affiliate market value was $494,049,876, and as of February 19, 2026, there were 93,508,165 shares outstanding and about 2,700 employees.